Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03674047 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase 2 study of Other Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT03674047 is a Phase 2 study of Other Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 3,257-participant average among 5 other Other Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT03674047, a Phase 2 study of Other Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This research study is studying a drug as a possible treatment for Bronchiolitis Obliterans Syndrome (BOS) after having an Allogeneic Hematopoietic Cell Transplantation (HCT).
Conditions Studied
Interventions
- DRUG ruxolitinib
Study Locations (7)
California
- City of Hope Cancer Center - Duarte
Florida
- H. Lee Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Cleveland Clinic - Cleveland
Utah
- Huntsman Cancer Institute - Salt Lake City
Washington
- Fred Hutchinson Cancer Center - Seattle
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-04-19 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03674047
The ClinicalTrials.gov registry entry for NCT03674047 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,257-participant average among 5 other Other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Other Cancer appearing as the primary indexed condition, and to 1 intervention - of which ruxolitinib is the first listed.
NCT03674047 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03674047 about?
NCT03674047 is a clinical study titled "Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)". This research study is studying a drug as a possible treatment for Bronchiolitis Obliterans Syndrome (BOS) after having an Allogeneic Hematopoietic Cell Transplantation (HCT).
What is the current status of trial NCT03674047?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2019-04-19. Estimated completion is 2025-12.
What conditions does trial NCT03674047 study?
This clinical trial studies the following conditions: Other Cancer.
What interventions are being tested in trial NCT03674047?
The interventions under investigation include: ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03674047?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03674047 being conducted?
This trial has 7 study locations across California, Florida, Massachusetts, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Other Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
RECRUITING · NA
-
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
ACTIVE NOT RECRUITING · NA
-
Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly
COMPLETED · NA
-
A Geriatric Oncology Collaborative Care Intervention for Older Adults With Advanced Cancer
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.